<DOC>
	<DOCNO>NCT01375270</DOCNO>
	<brief_summary>Elevations blood glucose lipid think deleterious insulin secretory function pancreas . This known glucolipotoxicity . However , study examine detail . This investigation examine pancreatic insulin secretory function physiological model glucolipotoxicity obese type 2 diabetic individual . Furthermore , healthy subject undergo 24 hour infusion glucose Intralipid induce experimental model glucolipotoxicity . Insulin secretion response intravenous infusion glucose , GLP-1 , GIP , arginine response meal ingestion , examine . investigator hypothesize experimental glucolipotoxicity impairs pancreatic insulin secretory function level akin see type 2 diabetic .</brief_summary>
	<brief_title>Glucolipotoxicity Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>normal glucose tolerance base screen OGTT diagnose type 2 diabetic ( confirmed OGTT ) insulin dependent diabetes age &lt; 18 &gt; 65 year BMI &lt; 20 &gt; 35 kg/m2 evidence hematological , pulmonary , hepatic , renal , cardiovascular disease actively undergoing weightloss ( &gt; 2kg change last 6 month ) bariatric surgery ( gastric bypass banding ) pregnancy smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>incretin</keyword>
	<keyword>beta-cell function</keyword>
	<keyword>glucolipotoxicity</keyword>
	<keyword>glucagon-like peptide 1</keyword>
	<keyword>glucose-dependent insulinotropic polypeptide</keyword>
</DOC>